BackMBX Biosciences Common Stock Overview

MBX Biosciences Common Stock Other Current Assets

Track MBX Biosciences Common Stock's other current assets ($8.6M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Current Assets
$8.56M
145.24% YoYΔ $5.07M vs prior year quarter

Peer average

Loading

MBX Biosciences Common Stock Other Current Assets History

Loading

MBX Biosciences Common Stock vs. peers: Other Current Assets Comparison

Loading

MBX Biosciences Common Stock Other Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

MBX Biosciences Common Stock (MBX) FAQ

MBX Biosciences Common Stock (MBX) currently reports a other current assets of $8.6M as of March 2026. That compares with $3.5M in the prior-year period — up 145.2% year over year. Use the charts on this page to explore MBX Biosciences Common Stock's other current assets history and peer comparisons.

MBX Biosciences Common Stock's other current assets increased from $3.5M to $8.6M — a 145.2% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

MBX Biosciences Common Stock reported $8.6M in other current assets as of March 2026. That compares with $3.5M in the prior-year period — up 145.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current assets of $8.6M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for MBX Biosciences Common Stock, and consider following MBX for alerts when major investors trade the stock.

MBX Biosciences Common Stock is classified in the Healthcare sector. On other current assets, it currently shows $8.6M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MBX with unrelated industries.